Oligonucleotide Manufacturers are Actively Investing and Collaborating to Expandingby Srishti K. Roots Analysis provides market research and consul
In the pharmaceutical industry, stakeholders are known to adopt a variety partnerships and expansion models. Such initiatives not only allow the companies to expand their respective product / service portfolio, but also to gain additional capabilities in emerging technologies. Owing to the complexities associated with synthesis of oligonucleotides and requirement of complex analytical expertise, several service providers have made significant investments to expand their respective production capabilities and capacities. Certain players have also established new manufacturing facilities in order to cater to the growing demand for these molecules.
During our research, we came across 32 expansions, reported in the public domain during the period 2014-2019. Majority (15) of the expansion initiatives within this domain were observed to be carried out for strengthening the manufacturing related operations. Further, over 60% of the instances were focused on expanding all the scales of operations. In North America, 50% of the instances were of capability expansion, while 25% were aimed at establishment of new manufacturing facilities. A similar trend was observed in Europe, where 50% of the expansions were focused on capability expansion of existing facilities and 38% were aimed at establishment of new facilities.
The field has also witnessed the establishment of multiple partnerships between drug developers or equipment suppliers and contract service providers, in the past few years. During our research, we came across close to 35 partnership agreements, inked during the period 2014-2019. It is worth highlighting that the maximum number of partnerships (10) were recorded in 2016; of these, eight agreements were signed in the second half of the year.
It is worth mentioning that, majority (21%) of the instances were reported to be manufacturing and supply agreements, followed by mergers / acquisitions (20%). Most of the agreements (69%) within this domain were signed between industry players located in the same region. Furthermore, in most of the intercontinental agreements, the leading partner (company providing services related to oligonucleotides) was observed to be based in North America.
Created on Jun 18th 2020 02:43. Viewed 23 times.